Research News
View articles by month and year
11–20 of 26 articles
-
Chemo During Pregnancy Doesn’t Harm Baby
New research supports other studies that suggest that chemotherapy during pregnancy doesn't have harmful effects on the baby.
-
Taxotere Better Than Fluorouracil in Chemo Regimen After Surgery for Early-Stage Disease
Chemotherapy that included Taxotere offered slightly better results than a regimen that included 5-FU for women diagnosed with early-stage breast cancer that hadn't spread to the lymph nodes, but Taxotere was more likely to cause serious side effects.
-
Halaven Approved by FDA to Treat Metastatic Breast Cancer
The FDA has approved a new chemotherapy medicine, Halaven (chemical name: eribulin), to treat metastatic breast cancer that already has been treated with other chemotherapy medicines.
-
Chemotherapy Before Surgery Can Benefit Advanced-Stage, Triple-Negative Breast Cancer
A small, early study found that 66% of locally-advanced, triple-negative breast cancers treated before surgery with a combination of carboplatin and Taxotere had no living cancer cells in the tumor when it was removed.
-
Giving Chemo Medicines Sequentially May Have Advantages
Treating early-stage breast cancer with two chemotherapy medicines followed by a third seems to have some advantages compared to giving two or three medicines at the same time, but may cause more severe side effects.
-
Zometa with Chemo Before Surgery Helps Kill Breast Cancer Cells in Bone Marrow
Research suggests that adding Zometa to chemotherapy given before early-stage breast cancer surgery may destroy breast cancer cells that have traveled to the bone marrow in some women.
-
New Treatment Standard Offered for Metastatic HER2-Positive Disease
A new study suggests that the combination of Navelbine and Herceptin may be better than Taxotere and Herceptin as the first treatment for HER2-positive, metastatic breast cancer.
-
Herceptin Plus Chemotherapy Without Anthracycline Effective
The latest results from the BCIRG-006 trial found that Herceptin plus chemotherapy that didn't include an anthracycline was as effective as Herceptin plus chemotherapy that did include an anthracycline for women diagnosed with HER2-positive, early-stage breast cancer.
-
Taxanes Only Reduce Recurrence Risk for Certain Types of Breast Cancer
Research shows that taxanes (a type of chemotherapy medicine) reduce the risk of recurrence of only certain types of breast cancer, so using taxanes to treat the other types of disease doesn't offer any real benefits.
-
Adding Taxotere to Standard Chemo Doesn’t Seem to Help Treat Early-Stage Breast Cancer
Taxotere doesn't seem to offer any benefits in treating early-stage breast cancer and also causes more serious side effects.
11–20 of 26 articles
